Building on the concept of FLT3 inhibition in FLT3-mutated AML, the potent and selective FLT3 type 2 inhibitor quizartinib was recently evaluated for efficacy in terms of OS prolongation in patients with FLT3-ITD+ AML (n = 539, 18–75 years old). The gene discussed is FLT3; the disease is acute myeloid leukemia.